

FILE 'REGISTRY' ENTERED AT 15:50:18 ON 25 SEP 2008
L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 13 S L3
L5 2762 S L3 SSS FULL

FILE 'HCAPLUS' ENTERED AT 15:52:40 ON 25 SEP 2008
L6 312 S L5/THU
L7 327499 S INFLAMM?
L8 321955 S DERMATOL? OR SKIN OR TOPICAL
L9 35 S L6 AND L7 AND L8
L10 25 S L9 AND (PY<2004 OR AY<2004 OR PRY<2004)
L11 77588 S ECZEMA OR DERMATITIS OR ACNE OR PSORIASIS OR VITILIGO OR PITY
L12 10 S L10 AND L11

```
=> file registry
COST IN U.S. DOLLARS
SINCE FILE      TOTAL
ENTRY          SESSION
FULL ESTIMATED COST      0.21      0.21
```

FILE 'REGISTRY' ENTERED AT 15:50:18 ON 25 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2008 HIGHEST RN 1052402-74-0
DICTIONARY FILE UPDATES: 24 SEP 2008 HIGHEST RN 1052402-74-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=>
Uploading C:\Program Files\STNEXP\Queries\10577444glycoside.str
```



```
chain nodes :
7 9 10 11 13 14 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6
chain bonds :
1-14 1-18 2-15 2-17 3-7 3-16 5-10 5-20 6-13 6-19 7-9 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-14 2-3 2-15 3-4 4-5 5-6 5-10 6-13 7-9 10-11
exact bonds :
1-18 2-17 3-7 3-16 5-20 6-19


G1:H,OH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 9:CLASS 10:CLASS 11:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
Generic attributes :
11:
Saturation           : Saturated
```

Element Count :
Node 11: Limited
C,C2-40

L1 STRUCTURE UPLOADED

```
=> d l1  
L1 HAS NO ANSWERS  
L1 STB
```



G1 H₂OH

Structure attributes must be viewed using STN Express query preparation.

=> S 11
SAMPLE SEARCH INITIATED 15:50:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 18751 TO ITERATE

10.7% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00:00:01



FULL FILE PROJECTIONS: ONLINE **COMPLETE**
PROJECTED ITERATIONS: 366820 TO 383220
PROJECTED ANSWERS: 19057 TO 22945

1.2 50 SEA SSS SAM 1.1

=> d 12 scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzoic acid, 3,5-bis[2-[3-[1-[3-(β -D-galactopyranosyloxy)propyl]-1H-1,2,3-triazol-4-yl]-1-oxopropyl]amino]ethoxy]-, methyl ester
MF C40 H60 N8 O18

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN β-D-Glucopyranoside, octyl O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→6)]-O-α-D-mannopyranosyl-(1→6)-
 MF C36 H64 N2 O21


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN β -D-Galactopyranoside, (1S)-2-(3-cyclohexyl-1-oxopropoxy)-1-(hydroxymethyl)ethyl, 6-cyclohexanepropanoate
 MF C₂₇ H₄₆ O₁₀

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 50 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN β -Cyclodextrin, 6A-deoxy-6A-[[[2-(α -D-mannopyranosyloxy)-1,1-


bis[(α -D-mannopyranosyloxy)methyl]ethyl]amino]thioxomethyl]amino]-,
compd. with (α R, β S)-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-12b-
(acetoxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-
4, 6, 11-trihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-
cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl β -[(1, 1-
dimethylethoxy)carbonyl]amino]- α -hydroxybenzenepropanoate (1:1)
(9CI)

MF C65 H110 N2 O52 S . C43 H53 N O14

CM 1


Absolute stereochemistry.

PAGE 1-A




PAGE 2-A





CM 2

Absolute stereochemistry. Rotation (-).



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\STNEXP\Queries\10577444glycoside2.str



```
chain nodes :  
7 9 10 11 13 14 15 16 17 18 19 20  
ring nodes :  
1 2 3 4 5 6  
chain bonds :  
1-14 1-18 2-15 2-17 3-7 3-16 5-10 5-20 6-13 6-19 7-9 10-11  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
exact/norm bonds :  
1-2 1-6 1-14 2-3 2-15 3-4 4-5 5-6 5-10 6-13 7-9 10-11  
exact bonds :  
1-18 2-17 3-7 3-16 5-20 6-19
```

G1:H,OH

```
Connectivity :  
11:1 X maximum RC ring/chain  
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 9:CLASS 10:CLASS 11:CLASS  
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS  
Generic attributes :
```

11:
Saturation : Saturated
Element Count :
Node 11: Limited
C,C2-40

L3 STRUCTURE UPLOADED

=> s 13
SAMPLE SEARCH INITIATED 15:51:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 18751 TO ITERATE

10.7% PROCESSED 2000 ITERATIONS 13 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 366820 TO 383220
PROJECTED ANSWERS: 1775 TO 3099

L4 13 SEA SSS SAM L3

=> d 14 scan

L4 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN β-D-Glucopyranoside, 1-methylheptyl
MF C14 H28 O6

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L4 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN β -D-Galactopyranoside, ethyl
MF C8 H16 O6

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN D-Glucopyranoside, tetradearyl O-D-glucopyranosyl-, bis(hydrogen sulfate),
disodium salt (9CI)
MF C26 H50 O17 S2 . 2 Na
CI IDS

CM 1

Absolute stereochemistry.




CM 2




CM 3

Absolute stereochemistry.



L4 13 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN β-D-Glucopyranoside, (3S,7R,11R)-3,7,11,15-tetramethylhexadecyl
MF C26 H52 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 13 sss full
FULL SEARCH INITIATED 15:52:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 379470 TO ITERATE

100.0% PROCESSED 379470 ITERATIONS 2762 ANSWERS
SEARCH TIME: 00.00.07

L5 2762 SEA SSS FUL L3

	SINCE FILE	TOTAL
	ENTRY	SESSION
=> file hcaplus		
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	179.74	179.95

FILE 'HCAPLUS' ENTERED AT 15:52:40 ON 25 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2008 VOL 149 ISS 13
FILE LAST UPDATED: 24 Sep 2008 (20080924/ED)

HCplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15/thu
 4076 L5
 1051205 THU/RL
L6 312 L5/THU
 (L5 (L) THU/RL)

=> s inflamm?
L7 327499 INFLAMM?

=> s dermatol? or skin or topical
 9436 DERMATOL?
 287471 SKIN
 51914 TOPICAL
L8 321955 DERMATOL? OR SKIN OR TOPICAL

=> s 16 and 17 and 18
L9 35 L6 AND L7 AND L8

=> s 19 and (PY<2004 or AY<2004 or PRY<2004)
 24009649 PY<2004
 4786561 AY<2004
 4257856 PRY<2004
L10 25 L9 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> d 110 1-25 ti abs bib

L10 ANSWER 1 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN
TI Nanoparticulate compositions of angiogenesis inhibitors
AB Nanoparticulate compns. comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compns. have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compns. For example, a nanoparticulate dispersion was prepared by milling a mixture containing 5% 2-methoxyestradiol, 1% hydroxypropyl cellulose of low viscosity (HPC-SL), and 0.05% docusate sodium (DOSS). The mean particle size of the nanoparticulate dispersion of 2-methoxyestradiol was 153 nm, with 50% < 144 nm, 90% < 217 nm, and 95% < 251 nm. After 2 wk storage at 5°, the nanoparticulate dispersion of 2-methoxyestradiol had a mean particle

size of 195 nm.

AN 2008:1100511 HCPLUS <>LOGINID::20080925>>

TI Nanoparticulate compositions of angiogenesis inhibitors

IN Merisko-Liversidge, Elaine; Bosch, H. William; Cary, Greta G.; Pruitt, John; Ryde, Tuula; Jain, Rajeev; Walters, Amy

PA Elan Pharma International Ltd., USA

SO U.S. Pat. Appl. Publ., 17pp., Cont.-in-part of U.S. Ser. No. 392,403.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 200802220075	A1	20080911	US 2008-76247	20080314 <--
	US 20040033267	A1	20040219	US 2003-392403	20030320 <--
	EP 1800666	A1	20070627	EP 2006-22201	20030320 <--
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	US 20080050461	A1	20080228	US 2007-928250	20071030 <--
	US 20080107741	A1	20080508	US 2007-928278	20071030 <--
	US 20080226732	A1	20080918	US 2007-928289	20071030 <--
PRAI	US 2002-365540P	P	20020320	<--	
	US 2002-366542P	P	20020325	<--	
	US 2003-392403	A2	20030320	<--	
	EP 2003-723781	A3	20030320	<--	

L10 ANSWER 2 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN

TI Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

AB The present invention relates to a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixts. thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixts. thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and/or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant. Thus, a foaming vehicle composition comprised (i) an oil phase containing diisopropyl adipate (DISPA) 20.00, benzyl alc. 2.00, oleyl alc. 20.00, PPG 15 stearyl ether 2.00, sorbitan stearate 2.00, and stearyl alc. 3.00, and (ii) a water phase containing hydroxypropyl Me cellulose 0.15, xanthan gum 0.15, sucrose ester 3.00, propylene glycol 17.70, and water 30.00%, resp.

AN 2008:226051 HCPLUS <>LOGINID::20080925>>

DN 148:269446

TI Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

IN Tamarkin, Dov; Friedman, Doron; Berman, Tal; Ziv, Enbal; Schuz, David

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S. Ser. No. 717,897.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080044444	A1	20080221	US 2007-825406	20070705 <--
	WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
	WO 2004037225	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 20050031547 A1 20050210 US 2004-835505 20040428 <--
 US 20050069566 A1 20050331 US 2004-911367 20040804 <--
 AU 2004313285 A1 20050929 AU 2004-313285 20041216 <--
 US 20050232869 A1 20051020 US 2005-78902 20050311 <--
 ZA 2005003298 A 20060830 ZA 2005-3298 20050425 <--
 US 20060140984 A1 20060629 US 2005-532618 20051222 <--
 AU 2006201878 A1 20070927 AU 2006-201878 20060504 <--
 US 20070280891 A1 20071206 US 2006-645444 20061226 <--
 US 20070292461 A1 20071220 US 2007-653205 20070112 <--
 US 20070253911 A1 20071101 US 2007-717897 20070313 <--
 WO 2008038147 A2 20080403 WO 2007-IB3759 20070705
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
 GB, GD, GE, GH, GM, GT, HH, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 US 20080050317 A1 20080228 US 2007-894668 20070820 <--
 PRAI IL 2002-152486 A 20021025 <--
 US 2002-429546P P 20021129 <--
 US 2003-492385P P 20030804 <--
 WO 2003-IB5527 W 20031024 <--
 US 2003-530015P P 20031216 <--
 US 2004-835505 A2 20040428
 US 2004-911367 A2 20040804
 US 2005-78902 A2 20050311
 US 2005-532618 A2 20051222
 US 2006-818634P P 20060705
 US 2007-653205 A2 20070112
 US 2007-717897 A2 20070313
 US 2005-679020P P 20050509
 US 2006-781868P P 20060313
 US 2006-784793P P 20060321
 US 2006-430599 A2 20060509
 US 2007-897638P P 20070126
 US 2007-899176P P 20070202

L10 ANSWER 3 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN
 TI Nanoparticulate fibrate formulations
 AB The present invention is directed to fibrate compns. having improved
 pharmacokinetic profiles and reduced fed/fasted variability. The fibrate
 particles of the composition have an effective average particle size of less
 than about 2000 nm. Thus, formulation was prepared containing fenofibrate 5%,
 hydroxypropyl cellulose 1%, and dioctyl sodium sulfosuccinate 0.05%.

AN 2007:1309211 HCPLUS <>LOGINID::20080925>>
 DN 147:528186
 TI Nanoparticulate fibrate formulations
 IN Ryde, Tuula; Gustow, Evan E.; Jain, Rajeev; Patel, Rakesh; Wilkins, Michael John
 PA Elan Pharma International, Ltd., Ire.
 SO U.S. Pat. Appl. Publ., 33pp., Cont.-in-part of U.S. Ser. No. 522,528.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070264348	A1	20071115	US 2007-710607	20070226 <--
	US 20030224058	A1	20031204	US 2003-370277	20030221 <--
	US 20050276974	A1	20051215	US 2003-444066	20030523 <--
	US 7276249	B2	20071002		
PRAI	US 2002-383294P	P	20020524	<--	
	US 2003-370277	B2	20030221	<--	
	US 2003-444066	A2	20030523	<--	
	US 2005-275278	B1	20051221		
	US 2006-522528	B2	20060918		

L10 ANSWER 4 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN
 TI Compositions comprising telmesteine, glycyrrhetic acid, and a proanthocyanidin for the treatment of inflammatory conditions of mucosae, skin and the eye
 AB The present invention relates to compns. comprising telmesteine, glycyrrhetic acid, and a proanthocyanidin, as well as methods for using such compns. in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis(eczema), allergic contact dermatitis, seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. The present invention also relates to compns. comprising a proanthocyanidin, glycyrrhetic acid and telmesteine, as well as methods for using such compns. in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. Thus, a topical composition contained ethylhexyl palmitate 9.0, Bytrospermum parkii 6.0, pentylene glycol 5.0, arachidyl alc./ behenyl alc. 4.0, arachidyl glucoside/glyceryl stearate/PEG-100 stearate 3.0, butylene glycol 3.0, glycyrrhetic acid 2.0, capryloyl glycine 1.5, bisabolol 1.2, tocopheryl acetate 1.0, salicylic acid 1.0, NaOH 0.785, Carbomer 0.7, ethylhexyl glycerin 0.6, piroctone olamine 0.5, allantoin 0.35, DMDM hydantoin 0.3, proanthocyanidins from Vitis vinifera 0.1, disodium EDTA 0.08, tetrahexyldecyl ascorbate 0.05, Pr gallate 0.02, telmesteine 0.01, and water 59.805%, resp.
 AN 2007:958801 HCPLUS <>LOGINID::20080925>>
 DN 147:308200
 TI Compositions comprising telmesteine, glycyrrhetic acid, and a proanthocyanidin for the treatment of inflammatory conditions of mucosae, skin and the eye
 IN Mastrodonato, Marco; Ciattini, Roberto
 PA Sinclair Pharmaceuticals, Ltd., UK
 SO U.S., 13pp.
 CODEN: USXXAM
 DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 7262180	B2	20070828	US 2004-963848	20040102 <--
US 20050143324	A1	20050630		
IT 2002MI0756	A1	20031009	IT 2002-MI756	20020409 <--
WO 2003084553	A1	20031016	WO 2003-EP3329	20030331 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20060247183	A1	20061102	US 2006-358747	20060221 <--
US 20080015155	A1	20080117	US 2007-841564	20070820 <--
US 20080114057	A1	20080515	US 2008-13244	20080111 <--
PRAI IT 2002-MI756	A	20020409	<--	
WO 2003-EP3329	A2	20030331	<--	
US 2004-963848	A1	20041012		
US 2006-358747	B1	20060221		

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN
TI Polymer-coated particles for the delivery of active agents
AB Particles of less than 100 μ , where an active agent is coated with a matrix of cationic and anionic polymers, are efficient vehicles for delivering active agents to tissues such as skin and mucosal membranes. Such particles are able to deliver compds. to skin with little associated irritation. Prior art topical formulations typically have the disadvantage of causing significant skin irritation. Thus, water-insol. all-trans-retinoic acid (ATRA) solid particles (2 weight%) were incorporated into high viscosity chitosan solns.(3 weight% solution of Protasan UP B 80/500 in 2.1 weight% glycolic acid and 0.03 weight%

sodium hydroxide) in the presence of soybean oil (17 weight%) by vigorous mixing to form a matrix. The viscosity of the matrix was initially 215,000 cps at 25° with appropriate spindle at 1.5 rpm. The emulsion was then mixed with a poly(acrylic acid) solution (0.5 weight%) at pH 6.3 and homogenized to make a gel containing retinoic acid microparticles of size < 10 μ m. The retinoic acid was highly stable in the chitosan microparticulates. The initial retinoic acid concentration was determined as 0.052%

at time 0 and 0.05% at 3 mo.

AN 2005:1220488 HCPLUS <>LOGINID::20080925>>

DN 143:483118

TI Polymer-coated particles for the delivery of active agents

IN Cattaneo, Maurizio V.

PA Ivrea Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2005107710	A2	20051117	WO 2005-US15789	20050506	
	WO 2005107710	A3	20070125			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	20040247632	A1	20041209	US 2004-839907	20040506 <--	
AU	2005240189	A1	20051117	AU 2005-240189	20050506	
CA	2565236	A1	20051117	CA 2005-2565236	20050506	
EP	1742612	A2	20070117	EP 2005-752145	20050506	
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU	CN 1972675	A	20070530	CN 2005-80014289	20050506
		JP 2007536259	T	20071213	JP 2007-511619	20050506
PRAI	US 2004-839907	A	20040506			
US	2004-634885P	P	20041209			
US	1999-171959P	P	19991223 <--			
WO	2000-US35319	W	20001222 <--			
US	2002-221307	A1	20020909 <--			
WO	2005-US15789	W	20050506			

L10 ANSWER 6 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN

TI Novel nanoparticulate nimesulide compositions

AB The present invention provides nanoparticulate nimesulide compns. The compns. preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide compns. An aqueous solution of 1% (weight/weight) Plasdene S-630 was combined with 4.25 g of nimesulide (5% weight/weight) and stirred for 1 h at 4200 rpm with chilled water

(10°) recirculated through the milling chamber. The process yielded a colloidal dispersion of nimesulide with a mean particle size of 150 nm, a D50 of 124 nm, a D90 of 256 nm, and a D95 of 293 nm.

AN 2005:490281 HCPLUS <>LOGINID::20080925>>

DN 143:48056

TI Novel nanoparticulate nimesulide compositions

IN Bosch, H. William; Wertz, Christian F.

PA Elan Pharma International Ltd., Ire.

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005051356	A1	20050609	WO 2003-US32731	20031031 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2544404 A1 20050609 CA 2003-2544404 20031031 <--
 AU 2003303744 A1 20050617 AU 2003-303744 20031031 <--
 EP 1684725 A1 20060802 EP 2003-815810 20031031 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK
 JP 2007522079 T 20070809 JP 2005-510942 20031031 <--
 PRAI WO 2003-US32731 W 20031031 <--
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN
 TI Nanoparticle compositions comprising antibodies for targeted delivery
 AB The present invention is directed to compns. of one or more nanoparticulate active agents, at least one PEG-derivatized surface stabilizer, and at least one antibody or fragment thereof, and methods of using such compns. for targeting delivery of the one or more active agents to a desired site. The one or more active agents preferably have a particle size of $\leq 2 \mu$. The targeted delivery can be used, e.g., for disease diagnosis, imaging, or drug delivery. Thus, WIN-68209 particles were stabilized by PEG-DSPE stabilizer.
 AN 2005:472002 HCPLUS <>LOGINID::20080925>>
 DN 143:13359
 TI Nanoparticle compositions comprising antibodies for targeted delivery
 IN Liveridge, Elaine; Cunningham, James
 PA Elan Pharma International Ltd., Ire.
 SO PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005049091	A2	20050602	WO 2004-US37246	20041109 <--
	WO 2005049091	A3	20061109		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	20050147664	A1	20050707	US 2004-979792	20041103 <--
CA	2545856	A1	20050602	CA 2004-2545856	20041109 <--
EP	1689442	A2	20060816	EP 2004-810555	20041109 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
JP	2007511513	T	20070510	JP 2006-539722	20041109 <--
PRAI	US 2003-519251P	P	20031113 <--		
	WO 2004-US37246	W	20041109		

L10 ANSWER 8 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Alkyl-rhamnose or alkyl-fucose monomers, and drugs containing an alkyl-reducing sugar monomer

AB The present invention relates to new monomers of alkyl-rhamnose or alkyl-fucose. It also relates to a drug comprising at least a reducing alkyl-sugar monomer, this drug is advantageously intended to control the inflammatory mechanisms. It also relates to a method of cosmetic treatment with topical application of a composition containing at least a reducing

alkyl-sugar monomer. Dodecyl rhamnose was prepared by the reaction of dodecyl alc. with rhamnose. Dodecyl rhamnose at a concentration of 1.5 µm inhibited the adhesion of lymphocytes to the endothelial cells by 63%.

AN 2005:394096 HCAPLUS <>LOGINID:20080925>>

DN 142:435387

TI Alkyl-rhamnose or alkyl-fucose monomers, and drugs containing an alkyl-reducing sugar monomer

IN Houlmont, Jean Philippe; Rico, Lattes Isabelle; Perez, Emile; Bordat, Pascal

PA Pierre Fabre Dermo-Cosmetique, Fr.; Centre National de la Recherche Scientifique CNRS

SO Fr. Demande, 27 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2861729	A1	20050506	FR 2003-12798	20031031 <--
	FR 2861729	B1	20060908		
	CA 2544107	A1	20050512	CA 2004-2544107	20041029 <--
	WO 2005041983	A1	20050512	WO 2004-FR2794	20041029 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1682158	A1	20060726	EP 2004-805348	20041029 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IB, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004015623	A	20061212	BR 2004-15623	20041029 <--
	JP 2007509913	T	20070419	JP 2006-537367	20041029 <--
	US 20070134187	A1	20070614	US 2006-577444	20060427 <--
	MX 2006PA04822	A	20061129	MX 2006-PA4822	20060428 <--
PRAI	FR 2003-12798	A	20031031	<--	
	WO 2004-FR2794	W	20041029		

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Novel nanoparticulate metaxalone compositions comprising surface stabilizers and use for treating musculoskeletal disorders

AB The present invention relates to novel compns. of metaxalone, comprising metaxalone particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer that is preferably adsorbed to or associated with the surface of the drug particles. The

invention further discloses a method of making a nanoparticulate metaxalone composition comprising contacting metaxalone and at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate metaxalone composition. The one or more surface stabilizers can be contacted with metaxalone either before, preferably during, or after size reduction of the metaxalone. The present invention is also directed to methods of treatment using the nanoparticulate metaxalone compns. of the invention for treatment of musculoskeletal disorders.

AN 2005:158522 HCAPLUS <>LOGINID::20080925>>

DN 142:246155

TI Novel nanoparticulate metaxalone compositions comprising surface stabilizers and use for treating musculoskeletal disorders

IN Pruitt, John D.; Ryde, Tuula A.; Bosch, William H.

PA Elan Pharma International, Ltd., Ire.

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005016310	A1	20050224	WO 2004-US19108	20040726 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2534924	A1	20050224	CA 2004-2534924	20040726 <--
EP 1651189	A1	20060503	EP 2004-776615	20040726 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007501839	T	20070201	JP 2006-523181	20040726 <--
US 20050063913	A1	20050324	US 2004-912552	20040806 <--
PRAI US 2003-493446P	P	20030808 <--		
WO 2004-US19108	W	20040726		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Nanoparticulate sildenafil free base compositions

AB The present invention is directed to nanoparticulate compns. comprising sildenafil free base. The sildenafil free base particles have an effective average particle size of <2000 nm. Thus, 30 g the nanoparticulate sildenafil free base dispersion was added to 3.0 g mannitol and 1.5 g pullulan. A wafer tray was then filled by adding 0.5 g the diluted sildenafil free base dispersion to each 0.5-mL well and the wafer tray was then placed in a lyophilizer for 48 h to produce the final lyophilized wafer dosage form.

AN 2005:136521 HCAPLUS <>LOGINID::20080925>>

DN 142:225784

TI Nanoparticulate sildenafil free base compositions

IN Ryde, Tuula A.; Hovey, Douglas C.; Bosch, H. William
PA Elan Pharma International Ltd., Ire.

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013937	A2	20050217	WO 2004-US19106	20040723 <--
	WO 2005013937	A3	20050616		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	20050042177	A1	20050224	US 2004-895405	20040721 <--
CA	2533163	A1	20050217	CA 2004-2533163	20040723 <--
EP	1658053	A2	20060524	EP 2004-786037	20040723 <--
EP	1658053	B1	20080227		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP	2006528176	T	20061214	JP 2006-521069	20040723 <--
AT	387186	T	20080315	AT 2004-786037	20040723 <--
ES	2302035	T3	20080701	ES 2004-786037	20040723 <--
PRAI	US 2003-489101P	P	20030723	<--	
	WO 2004-US19106	W	20040723		

L10 ANSWER 11 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN

TI Nanoparticulate glipizide compositions

AB The present invention is directed to nanoparticulate compns. comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of <2 μ . Thus, a formulation contained spray-dried glipizide 5.33,mannitol 13.47,xylitol 40.53,citric acid 19.60,sodium bicarbonate 19.33,Asparatme 0.28,PEG-4000 0.93, and sodium stearyl fumarate 0.53%.

AN 2005:77981 HCPLUS <>LOGINID::20080925>

DN 142:162662

TI Nanoparticulate glipizide compositions

IN Bosch, H. William; Ryde, Niels P.

PA Elan Pharma International Limited, USA

SO U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 276,400.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 19

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	US 20050019412	A1	20050127	US 2003-701064	20031105 <--
	US 20020012675	A1	20020131	US 1999-337675	19990622 <--
	WO 2001087264	A2	20011122	WO 2001-US15983	20010518 <--
	WO 2001087264	A3	200200620		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20040013613	A1	20040122	US 2003-276400	20030115 <--
US 20080213378	A1	20080904	US 2007-980586	20071031 <--

PRAI US 1998-164351 B2 19981001 <--
 US 1999-337675 A2 19990622 <--
 WO 2001-US15983 W 20010518 <--
 US 2003-276400 A2 20030115 <--
 US 2000-572961 A 20000518 <--
 US 2002-387404P P 20020610 <--
 US 2003-457810 B1 20030610 <--
 US 2006-367716 A1 20060306

L10 ANSWER 12 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Nanoparticulate megestrol formulations containing surface stabilizer
 AB The present invention is directed to nanoparticulate compns. comprising
 megestrol. The megestrol particles of the composition have an effective
 average
 particle size of <2000 nm. Thus, a formulation contained megestrol 5,
 HPMC 1, and diethyl sodium sulfosuccinate 0.05%.
 AN 2005:36425 HCAPLUS <>LOGINID:20080925>>
 DN 142:120565
 TI Nanoparticulate megestrol formulations containing surface stabilizer
 IN Hovey, Douglas; Pruitt, John; Ryde, Tuula
 PA Elan Pharma International Ltd., USA
 SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 412,669.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20050008707	A1	20050113	US 2004-878623	20040629 <--
US 20030219490	A1	20031127	US 2003-412669	20030414 <--
US 7101576	B2	20060905		
US 20040105889	A1	20040603	US 2003-420927	20030423 <--
CA 2508301	A1	20040617	CA 2003-2508301	20030423 <--
WO 2004050059	A1	20040617	WO 2003-US12660	20030423 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003231071	A1	20040623	AU 2003-231071	20030423 <--
EP 1613276	A1	20060111	EP 2003-724196	20030423 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006510726	T	20060330	JP 2004-570751	20030423 <--
EP 1935407	A1	20080625	EP 2008-4947	20030423 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				
US 20050233001	A1	20051020	US 2005-93149	20050330 <--
US 20080152585	A1	20080626	US 2007-979253	20071031 <--
US 20080171088	A1	20080717	US 2007-980594	20071031 <--

PRAI US 2002-371680P P 20020412 <--
 US 2002-430348P P 20021203 <--

US 2003-412669	A2	20030414	<--
EP 2003-724196	A3	20030423	<--
US 2003-420927	A1	20030423	<--
WO 2003-US12660	W	20030423	<--
US 2004-878623	A1	20040629	
US 2005-93149	A1	20050330	

L10 ANSWER 13 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Novel griseofulvin compositions

AB The present invention is directed to nanoparticulate compns. comprising griseofulvin. The griseofulvin particles of the composition preferably have an effective average particle size of less than about 2 μm . Griseofulvin 5 % and Pluronic F127 2.5 % were combined in water and a slurry was then milled for 5 days. The nanoparticulate griseofulvin was combined with excipients to give a final composition containing griseofulvin 5, Pluronic F127 2.5, Na benzoate 0.2, Na saccharin 0.1, FD&C Red No.3 0.03 g, and water to 100 mL.

AN 2005:15931 HCAPLUS <>LOGINID::20080925>

DN 142:120508

TI Novel griseofulvin compositions

IN Liversidge, Gary G.

PA Elan Pharma International Limited, USA

SO U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 175,851.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20050004049	A1	20050106	US 2003-683154	20031014 <--
US 20010006617	A1	20010705	US 1997-815346	19970311 <--
US 6432381	B2	20020813		
US 20030054045	A1	20030320	US 2002-175851	20020621 <--
US 20070098805	A1	20070503	US 2006-546378	20061012 <--
PRAI US 1997-815346	A1	19970311	<--	
US 2002-175851	B2	20020621	<--	
US 1994-366841	A2	19941230	<--	
US 2003-683154	A3	20031014	<--	

L10 ANSWER 14 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Stabilized gelatin nanoparticulate active agent compositions

AB Disclosed is a solid or semi-solid gelatin nanoparticulate active agent dosage form comprising at least one nanoparticulate active agent and at least one gel-forming substance which exhibits gelation sufficient to retain excess water in the solid or semi-solid gelatin form. The active agent particles have an effective average diameter prior to inclusion in the dosage form of less than about 2000 nm. The dosage form of the invention has the advantages of easy administration combined with rapid dissolv. of the active agent following administration. For example, a nanoparticulate ketoprofen dispersion was prepared by milling 30% ketoprofen and 3% polyvinylpyrrolidone (PVP K90). The mean particle size of the ketoprofen dispersion was 183 nm, with a D50 and D90 of 178 nm and 249 nm, resp. A nanoparticulate dispersion was heated to 50° and then slowly added to the molten gelatin matrix (20% gelatin/80% water mixture). The resultant gelatin/nanoparticulate ketoprofen dispersion had the following composition: 15% ketoprofen, 1.5% PVP, and 10% gelatin with the remaining 73.5% of the composition being water. The molten mixture was homogenized and the formulation

was dispensed into a mold and refrigerated until formed.

AN 2005:14183 HCAPLUS <>LOGINID::20080925>

DN 142:120496

TI Stabilized gelatin nanoparticulate active agent compositions
IN McGurk, Simon L.; Czekai, David A.
PA Elan Pharma International Ltd., Ire.
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000265	A2	20050106	WO 2003-US28380	20030911 <--
	WO 2005000265	A3	20050512		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2498207	A1	20050106	CA 2003-2498207	20030911 <--
	AU 2003304237	A1	20050113	AU 2003-304237	20030911 <--
	US 20050031691	A1	20050210	US 2003-659706	20030911 <--
	EP 1553927	A2	20050720	EP 2003-816299	20030911 <--
	R: AI, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006514688	T	20060511	JP 2005-503259	20030911 <--
PRAI	US 2002-409587P	P	20020911	<--	
	WO 2003-US28380	W	20030911	<--	

L10 ANSWER 15 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Sterilization of dispersions of nanoparticulate active agents with gamma radiation

AB The present invention relates to methods for sterilization of dispersions of one or more nanoparticulate active agents via γ -irradiation and to the obtainable pharmaceutical compns. Exposure to γ -irradiation did not adversely affect the particle size distribution of the samples.

AN 2004:1059209 HCAPLUS <>LOGINID::20080925>

DN 142:43781

TI Sterilization of dispersions of nanoparticulate active agents with gamma radiation

IN Bosch, William H.; Keller, Janine

PA Elan Pharma International Ltd., Ire.

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004105809	A1	20041209	WO 2004-US14528	20040524 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 CA 2523035 A1 20041209 CA 2004-2523035 20040524 <--
 EP 1626742 A1 20060222 EP 2004-751758 20040524 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 JP 2007501683 T 20070201 JP 2006-532906 20040524 <--
 PRAI US 2003-472434P P 20030522 <--
 WO 2004-US14528 W 20040524
 RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Nanoparticulate topiramate formulations
 AB The present invention is directed to nanoparticulate compns. comprising
 topiramate. The topiramate particles of the composition have an effective
 average
 particle size of less than about 2 μ .
 AN 2004:754424 HCAPLUS <>LOGINID::20080925>>
 DN 141:282788
 TI Nanoparticulate topiramate formulations
 IN Gustow, Evan; Ryde, Tuula; Cooper, Eugene R.
 PA Elan Pharma International, Ltd., Ire.
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078162	A1	20040916	WO 2004-US2548	20040130 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2513064	A1	20040916	CA 2004-2513064	20040130 <--
	US 20040258758	A1	20041223	US 2004-766960	20040130 <--
	US 7390505	B2	20080624		
	EP 1587499	A1	20051026	EP 2004-706953	20040130 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006520814	T	20060914	JP 2006-508639	20040130 <--
PRAI	US 2003-444377P	P	20030131 <--		
	US 2003-477789P	P	20030612 <--		
	US 2003-511318P	P	20031016 <--		
	WO 2004-US2548	W	20040130		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Novel fluticasone formulations comprising a surface stabilizer
 AB The present invention is directed to fluticasone compns. comprising
 fluticasone and at least one surface stabilizer. The fluticasone
 particles of the composition preferably have an effective average particle
 size of <2000 nm. Thus, a formulation contained fluticasone propionate 5 and

Tyloxapol 2%.
 AN 2004:681556 HCPLUS <>LOGINID::20080925>>
 DN 141:212749
 TI Novel fluticasone formulations comprising a surface stabilizer
 IN Hovey, Douglas; Ryde, Tuula; Bosch, H. William
 PA Elan Pharma International Ltd., Ire.
 SO PCT Int. Appl., 63 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004069225	A1	20040819	WO 2004-US2980	20040203 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US	20040208833	A1	20041021	US 2004-768194	20040202 <--
CA	2514273	A1	20040819	CA 2004-2514273	20040203 <--
EP	1596830	A1	20051123	EP 2004-707728	20040203 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP	2006516646	T	20060706	JP 2006-503269	20040203 <--
PRAI	US 2003-444626P	P	20030204	<--	
	WO 2004-US2980	W	20040203		

L10 ANSWER 18 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN
 TI Milling microgram quantities of nanoparticulate candidate compounds
 AB The present invention is directed to a method of milling small quantities of one or more candidate compds. to reduce the particle size of at least one candidate compound to about 2 μm or less. The apparatus used for the milling process can be one or more multi-well plates, or any other suitable apparatus. The resultant products are dispersions of nanoparticulate candidate compds. The method is particularly suited for increasing the effectiveness of high throughput screening.

AN 2004:565063 HCPLUS <>LOGINID::20080925>>
 DN 141:99658
 TI Milling microgram quantities of nanoparticulate candidate compounds
 IN Cunningham, James; Merisko-Liversidge, Elaine; Cooper, Eugene R.;
 Liversidge, Gary G.
 PA Elan Pharma International Ltd., Ire.
 SO PCT Int. Appl., 72 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058216	A2	20040715	WO 2003-US39941	20031217 <--
	WO 2004058216	A3	20040910		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003297151 A1 20040722 AU 2003-297151 2003031217 <--
 PRAI US 2002-433784P P 20021217 <--
 WO 2003-US39941 W 20031217 <--

 L10 ANSWER 19 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Liquid dosage compositions of stable nanoparticulate drugs
 AB The present invention relates to liquid dosage compns. of stable nanoparticulate drugs. The liquid dosage compns. of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the drug. Thus, an aqueous nanoparticulate colloidal dispersion (NCD) comprising drug 32.5 Copovidone 6.5, and diocetyl sodium sulfosuccinate 0.464% by weight was prepared by milling for 3.8 h under high energy milling conditions. The final mean particle size (by weight) of the drug particles was 161 nm. The concentrated NCD was then diluted with preserved water and glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0% drug.
 AN 2004:60341 HCAPLUS <LOGINID::20080925>
 DN 140:117406
 TI Liquid dosage compositions of stable nanoparticulate drugs
 IN Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu, Shugian
 PA Elan Pharma International, Ltd, Ire.
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 19

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004006959	A1	20040122	WO 2003-US22187	20030716 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492488	A1	20040122	CA 2003-2492488	20030716 <--
AU 2003261167	A1	20040202	AU 2003-261167	20030716 <--
EP 15501457	A1	20050713	EP 2003-764723	20030716 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005536512	T	20051202	JP 2004-521891	20030716 <--
PRAI US 2002-396530P	P	20020716 <--		
WO 2003-US22187	W	20030716 <--		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 20 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Nanoparticulate formulations comprising HMG CoA reductase inhibitors (statins)
 AB The present invention is directed to nanoparticulate compns. comprising

statin such as lovastatin or simvastatin including a surface stabilizer. The statin particles of the composition have an effective average particle size of

<2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described. Thus, a formulation comprised lovastatin 5, HPC 1.25, and sodium dioctylsulfosuccinate 0.05%.

AN 2003:991324 HCAPLUS <>LOGINID::20080925>>

DN 140:47516

TI Nanoparticulate formulations comprising HMG CoA reductase inhibitors (statins)

IN Cooper, Eugene R.; Hovey, Douglas; Carey, Greta; Lindner, Marie; Liversidge, Elaine; Liversidge, Gary G.; Ryde, Tuula

PA Elan Pharma International, Ltd, Ire.

SO PCT Int. Appl., '76 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 19

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003103640	A1	20031218	WO 2003-US16206	20030610 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488499	A1	20031218	CA 2003-2488499	20030610 <--
AU 2003245313	A1	20031222	AU 2003-245313	20030610 <--
EP 1531799	A1	20050525	EP 2003-738952	20030610 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005532352	T	20051027	JP 2004-510760	20030610 <--
US 20080213378	A1	20080904	US 2007-980586	20071031 <--
PRAI US 2002-387404P	P	20020610	<--	
US 1998-164351	B2	19981001	<--	
US 1999-337675	A1	19990622	<--	
US 2003-457810	B1	20030610	<--	
WO 2003-US16206	W	20030610	<--	
US 2006-367716	A1	20060306		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 21 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Nanoparticulate polycosanol formulations

AB The present invention is directed to nanoparticulate compns. comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of <2000 nm. In another aspect of this invention, novel combinations of polycosanols and other cholesterol lowering agents are described. Two grades of polycosanol were evaluated, labeled OCTA-60 (Formulation A) and OCTA-95 (Formulation B). The 1-octacosanol content is 60% in Formulation A and 95% in Formulation B. Both contain a total of 97-98% long chain aliphatic alcs., such as 1-octacosanol, 1-triacontanol, 1-dotriacontanol, 1-hexacosanol, and 1-heptacosanol. The polycosanol particle sizes for Formulations A and B were measured. The product of higher purity, OCTA-95, produces a more

stable dispersion as indicated by the size before and after sonication. While the OCTA-60 formulation initially seems prone to aggregation, it relaxes into a more stable dispersion upon aging. Thus, both types of polycosanol are suitable for the nanoparticulate polycosanol compns.

AN 2003:991166 HCPLUS <<LOGINID::20080925>>
DN 140:47511
TI Nanoparticulate polycosanol formulations
IN Cooper, Eugene R.; Kline, Laura; Liversidge, Gary G.; Ryde, Niels P.
PA Elan Pharma International, Ltd., USA
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030232796	A1	20031218	US 2003-457811	20030610 <--
PRAI US 2002-387463P	P	20020610	<--	

L10 ANSWER 22 OF 25 HCPLUS COPYRIGHT 2008 ACS on STN
TI Nanoparticulate compositions having lysozyme as a surface stabilizer
AB The present invention is directed to nanoparticulate active agent compns. comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compns. comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compns. A method of making the composition comprises at least one active agent having lysozyme associated with the surface thereof in an amount sufficient to maintain the active agent particles at an effective average particle size of 5-2000 nm, by (a) dissolving the active agent particles in a solvent; (b) adding the resulting active agent solution to a solution comprising lysozyme; and (c) precipitating the solubilized active agent/lysozyme composition by the addition thereto of a non-solvent.

AN 2003:633443 HCPLUS <<LOGINID::20080925>>
DN 139:185664
TI Nanoparticulate compositions having lysozyme as a surface stabilizer
IN Wertz, Christian F.; Ryde, Niels P.
PA Elan Pharma International Ltd., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 19

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003066021	A2	20030814	WO 2003-US1083	20030204 <--
WO 2003066021	A3	20040401		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2475092	A1	20030814	CA 2003-2475092	20030204 <--
AU 2003210517	A1	20030902	AU 2003-210517	20030204 <--
EP 1471887	A2	20041103	EP 2003-737537	20030204 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005523900 T 20050811 JP 2003-565446 20030204 <--
 PRAI US 2002-353230P P 20020204 <--
 WO 2003-US1083 W 20030204 <--

 L10 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Combination of immediate release and controlled release pharmaceuticals
 AB Disclosed are compns. exhibiting a combination of immediate release and controlled release characteristics. The compns. comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least 1 active ingredient having a microparticulate particle size. Using a math. model, pharmacokinetic profiles were developed after single oral doses of a pharmaceutical formulation containing a drug having a single defined particle size. Small particles dissolve faster than larger particles, but that they also decay more rapidly. As a consequence, larger drug particles provide the longest blood plasma levels, although these same particles exhibit slow dissolution.
 AN 2003:300863 HCAPLUS <>LOGINID::20080925>>
 DN 138:326560
 TI Combination of immediate release and controlled release pharmaceuticals
 IN Cooper, Eugene R.; Ruddy, Stephen B.
 PA USA
 SO PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003030872	A2	20030417	WO 2002-US32314	20021011 <--
WO 2003030872	A3	20030731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463495	A1	20030417	CA 2002-2463495	20021011 <--
AU 2002334939	A1	20030422	AU 2002-334939	20021011 <--
US 20030137067	A1	20030724	US 2002-268928	20021011 <--
US 6908626	B2	20050621		
EP 1443912	A2	20040811	EP 2002-800993	20021011 <--
EP 1443912	B1	20070829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005508939	T	20050407	JP 2003-533905	20021011 <--
AT 371442	T	20070915	AT 2002-800993	20021011 <--
ES 2292848	T3	20080316	ES 2002-800993	20021011 <--
PRAI US 2001-328405P	P	20011012 <--		
WO 2002-US32314	W	20021011 <--		

L10 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Methods and polymer compositions for gene delivery
 AB The present invention provides novel compns. and formulations for

delivering anionic compds., particularly polynucleotides (DNA and RNA), across cellular boundaries (e.g., cellular membranes) either in vivo or in vitro. Thus, polylysine-graft PEG was allowed to react with 4-hydroxybenzylimino Me ester-HCl in MeOH and water. The compds. can be used as fluorescent probes.

AN 2001:617869 HCAPLUS <>LOGINID::20080925>>

DN 135:200446

TI Methods and polymer compositions for gene delivery

IN Lollo, Charles Peter; Banaszczyk, Mariusz; Chiou, Henry C.; Wu, Dongpei; Mullenin, Patricia M.; Carlo, Alison T.

PA The Immune Response Corporation, USA

SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001060415	A1	20010823	WO 2001-US5234	20010216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20030134420	A1	20030717	US 2002-211214	20020802 <--
PRAI US 2000-183516P	P	20000218		
WO 2001-US5234	A1	20010216		<--

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Use of alkyl glucosides for stabilization of flavones, flavanones and/or flavonoids, synergistic mixtures of flavones, flavanones and/or flavonoids with alkyl glucosides, and cosmetic and dermatological preparations containing such mixtures

AB Alkyl glucosides protect flavones, flavanones, and/or flavonoids in cosmetic and dermatol. preps. from photochem. and oxidative degradation and act synergistically with these compds. to protect the skin from photochem. and oxidative damage which could otherwise lead to skin aging and inflammatory processes. Thus, an oil-in-water cream contained cetostearyl glucoside 3.00, stearyl alc. 5.00, octyldodecanol 6.00, caprylic/capric triglyceride 3.00, Na Carbomer 0.10, isoquercetin 0.20, glycerin 3.00, perfume, preservative, dyes, antioxidants, and H2O to 100.00 weight%.

AN 2000:227945 HCAPLUS <>LOGINID::20080925>>

DN 132:255787

TI Use of alkyl glucosides for stabilization of flavones, flavanones and/or flavonoids, synergistic mixtures of flavones, flavanones and/or flavonoids with alkyl glucosides, and cosmetic and dermatological preparations containing such mixtures

IN Max, Heiner; Schoenrock, Uwe; Staeb, Franz; Untiedt, Sven

PA Beiersdorf A.-G., Germany

SO Ger. Offen., 22 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 19845271	A1	20000406	DE 1998-19845271	19981001 <--
EP 998898	A1	20000510	EP 1999-119016	19990928 <--
EP 998898	B1	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO AT 270083	T	20040715	AT 1999-119016	19990928 <--
ES 2222645	T3	20050201	ES 1999-119016	19990928 <--
PRAI DE 1998-19845271	A	19981001 <--		
RE.CNT 3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD			
	ALL CITATIONS AVAILABLE IN THE RE FORMAT			

=> s eczema or dermatitis or acne or psoriasis or vitiligo or pityriasis or scleroderma or (skin graft) or (rheumatoid arthritis)

5576 ECZEMA
21457 DERMATITIS
7866 ACNE
17681 PSORIASIS
1605 VITILIGO
277 PITYRIASIS
5158 SCLERODERMA
287471 SKIN
114636 GRAFT
1397 SKIN GRAFT
(SKIN(W) GRAFT)
38467 RHEUMATOID
54023 ARTHRITIS
34488 RHEUMATOID ARTHRITIS
(RHEUMATOID(W) ARTHRITIS)

L11 77588 ECZEMA OR DERMATITIS OR ACNE OR PSORIASIS OR VITILIGO OR PITYRIASIS OR SCLERODERMA OR (SKIN GRAFT) OR (RHEUMATOID ARTHRITIS)

=> s l10 and l11

L12 10 L10 AND L11

=> d l12 1-10 ti abs bib hitstr

L12 ANSWER 1 OF 10 HCPLUS COPYRIGHT 2008 ACS on STN

TI Nanoparticulate compositions of angiogenesis inhibitors

AB Nanoparticulate compns. comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compns. have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compns. For example, a nanoparticulate dispersion was prepared by milling a mixture containing 5% 2-methoxyestradiol, 1% hydroxypropyl cellulose of low viscosity (HPC-SL), and 0.05% docusate sodium (DOSS). The mean particle size of the nanoparticulate dispersion of 2-methoxyestradiol was 153 nm, with 50% < 144 nm, 90% < 217 nm, and 95% < 251 nm. After 2 wk storage at 5°, the nanoparticulate dispersion of 2-methoxyestradiol had a mean particle size of 195 nm.

AN 2008:1100511 HCPLUS <>LOGINID::20080925>

TI Nanoparticulate compositions of angiogenesis inhibitors

IN Merisko-Liversidge, Elaine; Bosch, H. William; Cary, Greta G.; Pruitt, John; Ryde, Tuula; Jain, Rajeev; Walters, Amy

PA Elan Pharma International Ltd., USA

SO U.S. Pat. Appl. Publ., 17pp., Cont.-in-part of U.S. Ser. No. 392,403.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080220075	A1	20080911	US 2008-76247	20080314 <--
	US 20040033267	A1	20040219	US 2003-392403	20030320 <--
EP	1800666	A1	20070627	EP 2006-22201	20030320 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR				
US	20080050461	A1	20080228	US 2007-928250	20071030 <--
US	20080107741	A1	20080508	US 2007-928278	20071030 <--
US	20080226732	A1	20080918	US 2007-928289	20071030 <--
PRAI	US 2002-365540P	P	20020320	<--	
	US 2002-366542P	P	20020325	<--	
	US 2003-392403	A2	20030320	<--	
	EP 2003-723781	A3	20030320	<--	

IT INDEXING IN PROGRESS

IT 29836-26-8, n-Octyl- β -D-glucopyranoside 58846-77-8,
 n-Decyl- β -D-glucopyranoside 59080-45-4, n-Hexyl
 β -D-glucopyranoside 59122-55-3, n-Dodecyl- β -D-
 glucopyranoside 78617-12-6, n-Heptyl- β -D-glucopyranoside
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nanoparticulate compns. of angiogenesis inhibitors)

RN 29836-26-8 HCPLUS

CN β -D-Glucopyranoside, octyl (CA INDEX NAME)

L12 ANSWER 2 OF 10 HCPLUS COPYRIGHT 2008 ACS on STN

TI Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

AB The present invention relates to a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixts. thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixts. thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and/or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant. Thus, a foaming vehicle composition comprised (i) an oil phase containing diisopropyl adipate (DISPA) 20.00, benzyl alc. 2.00, oleyl alc. 20.00, PPG 15 stearyl ether 2.00, sorbitan stearate 2.00, and stearyl alc. 3.00, and (ii) a water phase containing hydroxypropyl Me cellulose 0.15, xanthan gum 0.15, sucrose ester 3.00, propylene glycol 17.70, and water 30.00%, resp.

AN 2008:226051 HCPLUS <>LOGINID::20080925>>

DN 148:269446

TI Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

IN Tamarkin, Dov; Friedman, Doron; Berman, Tal; Ziv, Enbal; Schuz, David

PA Foamix Ltd., Israel

SO U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S. Ser. No. 717,897.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080044444	A1	20080221	US 2007-825406	20070705 <--
WO	2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
WO	2004037225	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 20050031547 A1 20050210 US 2004-835505 20040428 <--
 US 20050069566 A1 20050331 US 2004-911367 20040804 <--
 AU 2004131285 A1 20050929 AU 2004-313285 20041216 <--
 US 20050232869 A1 20051020 US 2005-78902 20050311 <--
 ZA 2005003298 A 20060830 ZA 2005-3298 20050425 <--
 US 20060140984 A1 20060629 US 2005-532618 20051222 <--
 AU 2006201878 A1 20070927 AU 2006-201878 20060504 <--
 US 20070280891 A1 20071206 US 2006-645444 20061226 <--
 US 20070292461 A1 20071220 US 2007-653205 20070112 <--
 US 20070253911 A1 20071101 US 2007-717897 20070313 <--
 WO 2008038147 A2 20080403 WO 2007-IB3759 20070705
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
 GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KM, KN, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 US 20080050317 A1 20080228 US 2007-894668 20070820 <--
 PRAI IL 2002-152486 A 20021025 <--
 US 2002-429546P P 20022129 <--
 US 2003-492385P P 20030804 <--
 WO 2003-IB5527 W 20031024 <--
 US 2003-530015P P 20031216 <--
 US 2004-835505 A2 20040428
 US 2004-911367 A2 20040804
 US 2005-78902 A2 20050311
 US 2005-532618 A2 20051222
 US 2006-818634P P 20060705
 US 2007-653205 A2 20070112
 US 2007-717897 A2 20070313
 US 2005-679020P P 20050509
 US 2006-781868P P 20060313
 US 2006-784793P P 20060321
 US 2006-430599 A2 20060509
 US 2007-897638P P 20070126
 US 2007-899176P P 20070202
 IT 27836-64-2, Lauryl glucoside
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dicarboxylic acid foamable vehicle and pharmaceutical compns. thereof)
 RN 27836-64-2 HCPLUS
 CN D-Glucopyranoside, dodecyl (CA INDEX NAME)

L12 ANSWER 3 OF 10 HCPLUS COPYRIGHT 2008 ACS on STN
 TI Compositions comprising telmesteine, glycyrrhetic acid, and a
 proanthocyanidin for the treatment of inflammatory conditions of
 mucosae, skin and the eye

AB The present invention relates to compns. comprising telmesteine, glycyrrhetic acid, and a proanthocyanidin, as well as methods for using such compns. in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis(eczema), allergic contact dermatitis , seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. The present invention also relates to compns. comprising a proanthocyanidin, glycyrrhetic acid and telmesteine, as well as methods for using such compns. in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. Thus, a topical composition contained ethylhexyl palmitate 9.0, Bytyrospermum parkii 6.0, pentylene glycol 5.0, arachidyl alc./ behenyl alc. 4.0, arachidyl glucoside/glyceryl stearate/PEG-100 stearate 3.0, butylene glycol 3.0, glycyrrhetic acid 2.0, capryloyl glycine 1.5, bisabolol 1.2, tocopheryl acetate 1.0, salicylic acid 1.0, NaOH 0.785, Carbomer 0.7, ethylhexyl glycerin 0.6, piroctone olamine 0.5, allantoin 0.35, DMDM hydantoin 0.3, proanthocyanidins from Vitis vinifera 0.1, disodium EDTA 0.08, tetrahexyldecyl ascorbate 0.05, Pr gallate 0.02, telmesteine 0.01, and water 59.80%, resp.

AN 2007:958801 HCAPLUS <>LOGINID::20080925>>

DN 147:308200

TI Compositions comprising telmesteine, glycyrrhetic acid, and a proanthocyanidin for the treatment of inflammatory conditions of mucosae, skin and the eye

IN Mastrodonato, Marco; Ciattini, Roberto

PA Sinclair Pharmaceuticals, Ltd., UK

SO U.S., 13pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7262180	B2	20070828	US 2004-963848	20041012 <--
	US 20050143324	A1	20050630		
IT	2002MI0756	A1	20031009	IT 2002-MI756	20020409 <--
WO	2003084553	A1	20031016	WO 2003-EP3329	20030331 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20060247183	A1	20061102	US 2006-358747	20060221 <--
	US 20080015155	A1	20080117	US 2007-841564	20070820 <--
	US 200800114057	A1	20080515	US 2008-13244	20080111 <--
PRAI	IT 2002-MI756	A	20020409	<--	
	WO 2003-EP3329	A2	20030331	<--	
	US 2004-963848	A1	20041012		
	US 2006-358747	B1	20060221		
IT	144982-05-8, Arachidyl glucoside 239797-88-7, Montanov				

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical compns. comprising telmesteine, glycyrrhetic acid,
 and proanthocyanidin for treatment of inflammation of mucosa,
 skin and eye)

RN 144982-05-8 HCPLUS
 CN D-Glucopyranoside, eicosyl (CA INDEX NAME)

L12 ANSWER 4 OF 10 HCPLUS COPYRIGHT 2008 ACS on STN

TI Polymer-coated particles for the delivery of active agents

AB Particles of less than 100 μ , where an active agent is coated with a matrix of cationic and anionic polymers, are efficient vehicles for delivering active agents to tissues such as skin and mucosal membranes. Such particles are able to deliver compds. to skin with little associated irritation. Prior art topical formulations typically have the disadvantage of causing significant skin irritation. Thus, water-insol. all-trans-retinoic acid (ATRA) solid particles (2 weight%) were incorporated into high viscosity chitosan solns.(3 weight% solution of Protasan UP B 80/500 in 2.1 weight% glycolic acid and 0.03 weight%

sodium hydroxide) in the presence of soybean oil (17 weight%) by vigorous mixing to form a matrix. The viscosity of the matrix was initially 215,000 cps at 25° with appropriate spindle at 1.5 rpm. The emulsion was then mixed with a poly(acrylic acid) solution (0.5 weight%) at pH 6.3 and homogenized to make a gel containing retinoic acid microparticles of size < 10 μ m. The retinoic acid was highly stable in the chitosan microparticulates. The initial retinoic acid concentration was determined as 0.052%

at time 0 and 0.05% at 3 mo.

AN 2005:1220488 HCPLUS <>LOGINID::20080925>>

DN 143:483118

TI Polymer-coated particles for the delivery of active agents

IN Cattaneo, Maurizio V.

PA Ivrea Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005107710	A2	20051117	WO 2005-US15789	20050506
	WO 2005107710	A3	20070125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SX, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040247632		A1	20041209	US 2004-839907	20040506 <-
AU 2005240189		A1	20051117	AU 2005-240189	20050506
CA 2565236		A1	20051117	CA 2005-2565236	20050506
EP 1742612		A2	20070117	EP 2005-752145	20050506
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,					

	HR, LV, MK, YU			
CN 1972675	A	20070530	CN 2005-80014289	20050506
JP 2007536259	T	20071213	JP 2007-511619	20050506
PRAI US 2004-839907	A	20040506		
US 2004-634885P	P	20041209		
US 1999-171959P	P	19991223	<--	
WO 2000-US35319	W	20001222	<--	
US 2002-221307	A1	20020909	<--	
WO 2005-US15789	W	20050506		
IT 27836-64-2, Lauryl glucoside				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(polymer-coated particles for drug delivery to skin and				
mucosal membranes)				
RN 27836-64-2 HCPLUS				
CN D-Glucopyranoside, dodecyl (CA INDEX NAME)				
L12 ANSWER 5 OF 10 HCPLUS COPYRIGHT 2008 ACS on STN				
TI Novel nanoparticulate nimesulide compositions				
AB The present invention provides nanoparticulate nimesulide compns. The compns. preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide compns. An aqueous solution of 1% (weight/weight) Plasdene S-630 was combined with 4.25 g of nimesulide (5% weight/weight) and stirred for 1 h at 4200 rpm with chilled water				
(10°) recirculated through the milling chamber. The process yielded a colloidal dispersion of nimesulide with a mean particle size of 150 nm, a D50 of 124 nm, a D90 of 256 nm, and a D95 of 293 nm.				
AN 2005:490281 HCPLUS <>LOGINID::20080925>				
DN 143:48056				
TI Novel nanoparticulate nimesulide compositions				
IN Bosch, H. William; Wertz, Christian F.				
PA Elan Pharma International Ltd., Ire.				
SO PCT Int. Appl., 87 pp.				
CODEN: PIXXD2				
DT Patent				
LA English				
FAN.CNT 1				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005051356	A1	20050609	WO 2003-US32731	20031031 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2544404	A1	20050609	CA 2003-2544404	20031031 <--
AU 2003303744	A1	20050617	AU 2003-303744	20031031 <--
EP 1684725	A1	20060802	EP 2003-815810	20031031 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
JP 2007522079	T	20070809	JP 2005-510942	20031031 <--
PRAI WO 2003-US32731	W	20031031 <--		
IT 29836-26-8, n-Octyl β -D-glucopyranoside			58846-77-8,	

n-Decyl β -D-glucopyranoside 59080-45-4, n-Hexyl
 β -D-glucopyranoside 59122-55-3, n-Dodecyl
 β -D-glucopyranoside 69984-73-2, n-Nonyl
 β D-glucopyranoside 78617-12-6, n-Heptyl
 β -D-glucopyranoside
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel nanoparticulate nimesulide compns.)
 RN 29836-26-8 HCPLUS
 CN β -D-Glucopyranoside, octyl (CA INDEX NAME)

L12 ANSWER 6 OF 10 HCPLUS COPYRIGHT 2008 ACS on STN
 TI Alkyl-rhamnose or alkyl-fucose monomers, and drugs containing an alkyl-reducing sugar monomer
 AB The present invention relates to new monomers of alkyl-rhamnose or alkyl-fucose. It also relates to a drug comprising at least a reducing alkyl-sugar monomer, this drug is advantageously intended to control the inflammatory mechanisms. It also relates to a method of cosmetic treatment with topical application of a composition containing at least a reducing alkyl-sugar monomer. Dodecyl rhamnose was prepared by the reaction of dodecyl alc. with rhamnose. Dodecyl rhamnose at a concentration of 1.5 μ m inhibited the adhesion of lymphocytes to the endothelial cells by 63%.
 AN 2005:394096 HCPLUS <>LOGINID::20080925>>
 DN 142:435387
 TI Alkyl-rhamnose or alkyl-fucose monomers, and drugs containing an alkyl-reducing sugar monomer
 IN Houlmont, Jean Philippe; Rico, Lattes Isabelle; Perez, Emile; Bordat, Pascal
 PA Pierre Fabre Dermo-Cosmetique, Fr.; Centre National de la Recherche Scientifique CNRS
 SO Fr. Demande, 27 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2861729	A1	20050506	FR 2003-12798	20031031 <--
FR 2861729	B1	20060908		
CA 2544107	A1	20050512	CA 2004-2544107	20041029 <--
WO 2005041983	A1	20050512	WO 2004-FR2794	20041029 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1682158	A1	20060726	EP 2004-805348	20041029 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004015623	A	20061212	BR 2004-15623	20041029 <--
JP 2007509913	T	20070419	JP 2006-537367	20041029 <--
US 20070134187	A1	20070614	US 2006-577444	20060427 <--
MX 2006PA04822	A	20061129	MX 2006-PA4822	20060428 <--
PRAI FR 2003-12798	A	20031031	<--	
WO 2004-FR2794	W	20041029		

IT 850996-98-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(alkyl-rhamnose or alkyl-fucose monomers, and drugs containing alkyl-reducing sugar monomer)

RN 850996-98-4 HCPLUS

CN α -L-Mannopyranoside, dodecyl 6-deoxy- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 10 HCPLUS COPYRIGHT 2008 ACS on STN

TI Nanoparticulate sildenafil free base compositions

AB The present invention is directed to nanoparticulate compns. comprising sildenafil free base. The sildenafil free base particles have an effective average particle size of <2000 nm. Thus, 30 g the nanoparticulate sildenafil free base dispersion was added to 3.0 g mannitol and 1.5 g pullulan. A wafer tray was then filled by adding 0.5 g the diluted sildenafil free base dispersion to each 0.5-mL well and the wafer tray was then placed in a lyophilizer for 48 h to produce the final lyophilized wafer dosage form.

AN 2005:136521 HCPLUS <>LOGINID::20080925>>

DN 142:225784

TI Nanoparticulate sildenafil free base compositions

IN Ryde, Tuula A.; Hovey, Douglas C.; Bosch, H. William

PA Elan Pharma International Ltd., Ire.

PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013937	A2	20050217	WO 2004-US19106	20040723 <--
	WO 2005013937	A3	20050616		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG
 US 20050042177 A1 20050224 US 2004-895405 20040721 <--
 CA 2533163 A1 20050217 CA 2004-2533163 20040723 <--
 EP 1658053 A2 20060524 EP 2004-786037 20040723 <--
 EP 1658053 B1 20080227
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 JP 2006528176 T 20061214 JP 2006-521069 20040723 <--
 AT 387186 T 20080315 AT 2004-786037 20040723 <--
 ES 2302035 T3 20080701 ES 2004-786037 20040723 <--
PRAI US 2003-489101P P 20030723 <--
 WO 2004-US19106 W 20040723
IT 29836-26-8, n-Octyl- β -D-glucopyranoside 58846-77-8,
 n-Decyl β -D-glucopyranoside 59080-45-4,
 n-Hexyl- β -D-glucopyranoside 59122-55-3, n-Dodecyl
 β -D-glucopyranoside 69984-73-2, Nonoyl β -D-
 glucopyranoside 78617-12-6, n-Heptyl- β -D-glucopyranoside
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nanoparticulate sildenafil free base compns.)
RN 29836-26-8 HCAPLUS
CN β -D-Glucopyranoside, octyl (CA INDEX NAME)

L12 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Milling microgram quantities of nanoparticulate candidate compounds
AB The present invention is directed to a method of milling small quantities of one or more candidate compds. to reduce the particle size of at least one candidate compound to about 2 μ m or less. The apparatus used for the milling process can be one or more multi-well plates, or any other suitable apparatus. The resultant products are dispersions of nanoparticulate candidate compds. The method is particularly suited for increasing the effectiveness of high throughput screening.
AN 2004:565063 HCAPLUS <>LOGINID::20080925>>
DN 141:99658
TI Milling microgram quantities of nanoparticulate candidate compounds
IN Cunningham, James; Merisko-Liversidge, Elaine; Cooper, Eugene R.;
 Liversidge, Gary G.
PA Elan Pharma International Ltd., Ire.
SO PCT Int. Appl., 72 PP.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058216	A2	20040715	WO 2003-US39941	20031217 <--
WO 2004058216	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003297151	A1	20040722	AU 2003-297151	20031217 <--
PRAI US 2002-433784P	P	20021217 <--		
WO 2003-US39941	W	20031217 <--		
IT 29836-26-8, n-Octyl- β -D-glucopyranoside 58846-77-8, n-Decyl β -D-glucopyranoside 59080-45-4, n-Hexyl				

β-D-glucopyranoside 59122-55-3, n-Dodecyl
 β-D-glucopyranoside 69984-73-2, n-Nonyl
 β-D-glucopyranoside 78617-12-6, n-Heptyl-β-D-
 glucopyranoside
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (milling microgram quantities of nanoparticulates with stabilizers for
 high throughput screening)
 RN 29836-26-8 HCPLUS
 CN β-D-Glucopyranoside, octyl (CA INDEX NAME)

L12 ANSWER 9 OF 10 HCPLUS COPYRIGHT 2008 ACS on STN
 TI Liquid dosage compositions of stable nanoparticulate drugs
 AB The present invention relates to liquid dosage compns. of stable nanoparticulate drugs. The liquid dosage compns. of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the drug. Thus, an aqueous nanoparticulate colloidal dispersion (NCD) comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate 0.464% by weight was prepared by milling for 3.8 h under high energy milling conditions. The final mean particle size (by weight) of the drug particles was 161 nm. The concentrated NCD was then diluted with preserved water and glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0% drug.
 AN 2004:60341 HCPLUS <>LOGINID::20080925>>
 DN 140:117406
 TI Liquid dosage compositions of stable nanoparticulate drugs
 IN Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu, Shuqian
 PA Elan Pharma International, Ltd, Ire.
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXKD2
 DT Patent
 LA English
 FAN.CNT 19

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004006959	A1	20040122	WO 2003-US22187	20030716 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492488	A1	20040122	CA 2003-2492488	20030716 <--
AU 2003261167	A1	20040202	AU 2003-261167	20030716 <--
EP 1551457	A1	20050713	EP 2003-764723	20030716 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005536512	T	20051202	JP 2004-521891	20030716 <--
PRAI US 2002-396530P	P	20020716 <--		
WO 2003-US22187	W	20030716 <--		
IT 29836-26-8, n-Octyl-β-D-glucopyranoside 58846-77-8, n-Decyl β-D-glucopyranoside 59080-45-4, n-Hexyl β-D-glucopyranoside 59122-55-3, n-DoDecyl β-D-glucopyranoside 69984-73-2, n-Nonyl β-D-glucopyranoside 78617-12-6, n-Heptyl				

β -D-glucopyranoside
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (liquid dosage compns. of stable nanoparticulate drugs)
 RN 29836-26-8 HCPLUS
 CN β -D-Glucopyranoside, octyl (CA INDEX NAME)

L12 ANSWER 10 OF 10 HCPLUS COPYRIGHT 2008 ACS on STN
 TI Nanoparticulate compositions having lysozyme as a surface stabilizer
 AB The present invention is directed to nanoparticulate active agent compns. comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compns. comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compns. A method of making the composition comprises at least one active agent having lysozyme associated with the surface thereof in an amount sufficient to maintain the active agent particles at an effective average particle size of 5-2000 nm, by (a) dissolving the active agent particles in a solvent; (b) adding the resulting active agent solution to a solution comprising lysozyme; and (c) precipitating the solubilized active agent/lysozyme composition by the addition thereto of a non-solvent.
 AN 2003:633443 HCPLUS <>LOGINID::20080925>>
 DN 139:185664
 TI Nanoparticulate compositions having lysozyme as a surface stabilizer
 IN Wertz, Christian F.; Ryde, Niels P.
 PA Elan Pharma International Ltd., USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 19

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066021	A2	20030814	WO 2003-US1083	20030204 <--
WO 2003066021	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2475092	A1	20030814	CA 2003-2475092	20030204 <--
AU 2003210517	A1	20030902	AU 2003-210517	20030204 <--
EP 1471887	A2	20041103	EP 2003-737537	20030204 <--
R: AI, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005523900	T	20050811	JP 2003-565446	20030204 <--
PRAI US 2002-353230P	P	20020204	<--	
WO 2003-US1083	W	20030204	<--	
IT 29836-26-8, n-Octyl β -D-glucopyranoside 58846-77-8, n-Decyl β -D-glucopyranoside 59080-45-4, n-Hexyl β -D-glucopyranoside 59122-55-3, n-Dodecyl β -D-glucopyranoside 69984-73-2, n-Nonyl β -D-glucopyranoside 78617-12-6, n-Heptyl β -D-glucopyranoside				
RL: AGR (Agricultural use); COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(secondary surface stabilizer; nanoparticulate compns. having lysozyme				

as surface stabilizer for therapeutics and cosmetics and agrochems.)
RN 29836-26-8 HCPLUS
CN β -D-Glucopyranoside, octyl (CA INDEX NAME)